Cargando…
Inflammatory activity and vitamin D levels in an MS population treated with rituximab
BACKGROUND: Most multiple sclerosis patients on disease-modifying treatment at Umeå University Hospital are treated with rituximab and the prevalence of vitamin D supplementation has increased over time. Follow-up studies of these off-label treatments are needed. OBJECTIVE: To study inflammatory act...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378455/ https://www.ncbi.nlm.nih.gov/pubmed/30800416 http://dx.doi.org/10.1177/2055217319826598 |
_version_ | 1783395933425238016 |
---|---|
author | Linden, Johan Granåsen, Gabriel Salzer, Jonatan Svenningsson, Anders Sundström, Peter |
author_facet | Linden, Johan Granåsen, Gabriel Salzer, Jonatan Svenningsson, Anders Sundström, Peter |
author_sort | Linden, Johan |
collection | PubMed |
description | BACKGROUND: Most multiple sclerosis patients on disease-modifying treatment at Umeå University Hospital are treated with rituximab and the prevalence of vitamin D supplementation has increased over time. Follow-up studies of these off-label treatments are needed. OBJECTIVE: To study inflammatory activity and adverse effects in rituximab-treated multiple sclerosis patients, and associations with 25-hydroxy-vitamin D levels. METHODS: Retrospectively collected data on repeated estimates of relapses, disability, side effects, magnetic resonance imaging, laboratory measures including 25-hydroxy-vitamin D levels and self-perceived health. RESULTS: In 272 multiple sclerosis patients with a mean follow-up of 43 months, we identified seven possible relapses during active rituximab treatment. On magnetic resonance imaging examination, new T2 lesions were seen in 1.3% (10 out of 792 scans), and 0.25% (two out of 785 scans) showed contrast enhancement. Adjusted 25-hydroxy-vitamin D levels in samples drawn close to all magnetic resonance images with new T2 lesions were lower compared to the remainder (62 vs. 81 nmol/l; P = 0.030). Levels of 25-hydroxy-vitamin D were associated with self-perceived health (r = 0.18, P = 0.041, n = 130) and C-reactive protein (r = –0.13, P = 0.042) but not with the risk of side effects. CONCLUSION: The inflammatory activity in this rituximab-treated multiple sclerosis population that increasingly used vitamin D supplementation was extremely low. Higher 25-hydroxy-vitamin D levels were associated with beneficial outcomes. |
format | Online Article Text |
id | pubmed-6378455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-63784552019-02-22 Inflammatory activity and vitamin D levels in an MS population treated with rituximab Linden, Johan Granåsen, Gabriel Salzer, Jonatan Svenningsson, Anders Sundström, Peter Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: Most multiple sclerosis patients on disease-modifying treatment at Umeå University Hospital are treated with rituximab and the prevalence of vitamin D supplementation has increased over time. Follow-up studies of these off-label treatments are needed. OBJECTIVE: To study inflammatory activity and adverse effects in rituximab-treated multiple sclerosis patients, and associations with 25-hydroxy-vitamin D levels. METHODS: Retrospectively collected data on repeated estimates of relapses, disability, side effects, magnetic resonance imaging, laboratory measures including 25-hydroxy-vitamin D levels and self-perceived health. RESULTS: In 272 multiple sclerosis patients with a mean follow-up of 43 months, we identified seven possible relapses during active rituximab treatment. On magnetic resonance imaging examination, new T2 lesions were seen in 1.3% (10 out of 792 scans), and 0.25% (two out of 785 scans) showed contrast enhancement. Adjusted 25-hydroxy-vitamin D levels in samples drawn close to all magnetic resonance images with new T2 lesions were lower compared to the remainder (62 vs. 81 nmol/l; P = 0.030). Levels of 25-hydroxy-vitamin D were associated with self-perceived health (r = 0.18, P = 0.041, n = 130) and C-reactive protein (r = –0.13, P = 0.042) but not with the risk of side effects. CONCLUSION: The inflammatory activity in this rituximab-treated multiple sclerosis population that increasingly used vitamin D supplementation was extremely low. Higher 25-hydroxy-vitamin D levels were associated with beneficial outcomes. SAGE Publications 2019-02-11 /pmc/articles/PMC6378455/ /pubmed/30800416 http://dx.doi.org/10.1177/2055217319826598 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Paper Linden, Johan Granåsen, Gabriel Salzer, Jonatan Svenningsson, Anders Sundström, Peter Inflammatory activity and vitamin D levels in an MS population treated with rituximab |
title | Inflammatory activity and vitamin D levels in an MS population treated with rituximab |
title_full | Inflammatory activity and vitamin D levels in an MS population treated with rituximab |
title_fullStr | Inflammatory activity and vitamin D levels in an MS population treated with rituximab |
title_full_unstemmed | Inflammatory activity and vitamin D levels in an MS population treated with rituximab |
title_short | Inflammatory activity and vitamin D levels in an MS population treated with rituximab |
title_sort | inflammatory activity and vitamin d levels in an ms population treated with rituximab |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378455/ https://www.ncbi.nlm.nih.gov/pubmed/30800416 http://dx.doi.org/10.1177/2055217319826598 |
work_keys_str_mv | AT lindenjohan inflammatoryactivityandvitamindlevelsinanmspopulationtreatedwithrituximab AT granasengabriel inflammatoryactivityandvitamindlevelsinanmspopulationtreatedwithrituximab AT salzerjonatan inflammatoryactivityandvitamindlevelsinanmspopulationtreatedwithrituximab AT svenningssonanders inflammatoryactivityandvitamindlevelsinanmspopulationtreatedwithrituximab AT sundstrompeter inflammatoryactivityandvitamindlevelsinanmspopulationtreatedwithrituximab |